The efficacy of time-based short-course acyclovir therapy in treatment of post-herpetic pain by Rasi, A. et al.
  
Original Article  
 
The efficacy of time-based short-course acyclovir therapy in treatment of 
post-herpetic pain  
 
Abbas Rasi1, Ashkan Heshmatzade Behzadi2, Mehrshad Rabet3, Amir Ahmad Nejat4, Arezoo 
Haghshenas 2, Jaleh Hassanloo2, Yasamin Honarbakhsh2, Nasir Dehghan2, Seyed Kamran Kamrava5 
 
1
Department of Dermatology, Hazrat-e-Rasul Hospital, Iran University of Medical Sciences and Health Services, 
Tehran, Iran 
2
Department of Dermatology, Iran University of Medical Science 
3Department of Dermatology, Shaheed Beheshti University of Medical Sciences, Iran University of Medical Science 
4
Department of Internal Medicine, Hazrat-e-Rasul Hospital, Iran University of Medical Sciences and Health 
Services, Tehran, Iran 
5Department of Othrhinolaryngology, 
.
Hazrat Rasoul Akram Hospital, School of Medicine, Iran University of Medical 
Sciences, Tehran, Iran 
 
Abstract 
Introduction: Various treatments have been used to manage post-herpetic neuralgia (PHN). Safe and effective therapies to prevent PHN are 
needed.  
Methodology: A clinical trial involving 152 patients diagnosed with acute herpes Zoster (HZ) was conducted to determine whether short-
course acyclovir therapy (800 mg five times a day for four days) can alleviate HZ-associated pain and prevent post-herpetic neuralgia (PHN).  
The patients were divided into two groups: Group 1 had a rash with a duration of less than 72 hours and Group 2 had a rash with a duration 
of more than 72 hours. To assess PHN, the patients categorized and assessed the severity of their symptoms using a four-point verbal rating 
scale (VRS). 
Results: By the fourth week, 134 out of 152 patients (88.2%) had complete pain response (CPR). Of these, 68 patients (89.5%) were from 
Group 1 and 66 from Group 2 (86.8%). After four weeks, the mean VRS scores had changed significantly in both groups compared to the 
scores at the beginning of study (p = 0.001), but there was no difference between the two groups (0.88 ± 0.66 Vs. 0.94 ± 0.72; p = 0.66) After 
three months no differences were observed in the treatment results between the two groups (0.51 ± 0.13 Vs.0.54 ± 0.19; p = 0.77). 
Conclusion: Short-course acyclovir therapy is an effective treatment for zoster and its efficacy in patients with a rash duration of more than 
72 hours is similar to that in patients with rash duration of less than 72 hours.  
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Introduction 
Herpes zoster (HZ) is caused by reactivation of 
the Varicella-Zoster Virus (VZV), which remains 
latent in the sensory ganglia after primary infection 
[1]. During the acute illness, the rash is often 
accompanied by pain, and the most frequent 
complication of HZ infection is post-herpetic 
neuralgia (PHN), defined as debilitating pain, the 
pathogenesis of which remains unclear [2,3]. The true 
incidence of post-herpetic neuralgia is difficult to 
establish and depends partly on the definition being 
used. The incidence of PHN increases with 
advancing age [4,5]. 
Prevention of PHN is therefore an objective of most 
studies in the treatment of herpes zoster. Therapeutic 
interventions to avoid PHN include antiviral agents, 
corticosteroids, tricyclic antidepressants, and 
combinations of these [6]. An accurate estimate of 
the frequency, duration, and clinical importance of 
PHN after a single episode of herpes zoster would be 
helpful in interpreting studies on the prevention of 
PHN and in counselling patients about the risk of 
long-term pain after acute episodes of herpes zoster. 
Acyclovir, an analogue of 2′-deoxyguanosine, has 
been proved to have an in-vitro antiviral activity 
against VZV [7].Since its introduction to medical 
treatment in 1983, acyclovir has become the most 
widely prescribed antiviral drug in the world [8,9].  
The benefits of acyclovir therapy during the acute 
phase of herpes zoster are established [10-13]. In 
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controlled trials, intravenous and oral doses of 
acyclovir in immunocompetent patients are 
associated with significant improvement in the rate of 
healing and severity of the acute pain of herpes zoster 
[6,10-13]. The effects of acyclovir on PHN are less 
clear-cut. Three studies comparing oral acyclovir 
with placebo [11-13] determined that the incidence of 
prolonged pain was lowered in acyclovir recipients. 
In contrast, some other studies which evaluated the 
effects of five to seven days of intravenous or oral 
acyclovir found no benefit with respect to prolonged 
pain [6,10]. Consequently, the efficacy of acyclovir 
after three days of zoster infection remains in doubt. 
A selective controlled clinical trial was therefore 
designed to compare the efficacy of oral acyclovir in 
patients who presented within three days of the onset 
of Zoster rash to its efficacy in patients who 
presented with Zoster rash with a duration between 
three to seven days. 
 
Methodology  
Selection of patients 
We conducted our clinical trial from January 
2004 to January 2008 in the dermatology outpatient 
department of Hazrat-e-Rasul Akram Hospital, 
Tehran, Iran. The number of the patients with HZ 
which were included in this study was 152. Subjects 
were immunocompetent patients of either gender, 
aged 50 years and above, attending our departments 
for treatment of zoster. Patients who presented within 
the day of the onset of rash were enrolled in Group 1 
(G1), and patients who presented after three days 
were enrolled in Group 2 (G2). The baseline clinical 
characteristics and disease severity were similar in 
both groups. The diagnosis of HZ was made on 
clinical criteria (painful coetaneous, dermatomal, 
unilateral, and papulo-vesicular lesions). Written 
consent to participate was obtained from each patient 
individually. The study was conducted in accordance 
with the principles stated in the Declaration of 
Helsinki and was approved by the ethics committee 
of the Iran University of Medical Sciences.  
Adverse events, both local and systemic, or inter-
current illness, were recorded at each visit and their 
relation to the trial drug was judged. Liver function 
tests were performed both at the first visit and at the 
end of the treatment period. We also performed 
urinary analysis and serum Creatinin (Cr) and Blood 
Urea Nitrogen (BUN) analysis each week to monitor 
for potential renal problems such as crystallization. 
Patients received no other treatments for HZ 
throughout the study period. Clinical assessment in 
each visit was performed by a single dermatologist. 
 
Assessment 
The efficacy measurement in this study was the 
existence and severity of pain. Follow-up visits were 
performed at the first week, second week, first month 
and third month after the rash onset. Patients were 
asked to categorize and assess the severity of their 
symptoms using the following four-point verbal 
rating scale (VRS): 0 (no pain); 1 (mild pain that 
does not interfere with daily activities); 2 (moderate 
pain that interferes with daily activities but does not 
cause sleeplessness); 3 (severe pain that causes 
sleeplessness); or 4 (very severe unbearable pain that 
was extremely incapacitating) [14].  
Acute HZ pain intensity response was scored by 
the patient and was defined as the following: (I) Mild 
pain after treatment indicated 75% improvement, and 
complete pain relief was classified as 100% 
improvement. This level of pain reduction was 
classified as Complete Pain Response (CPR). These 
patients had either no pain or mild pain and could 
sleep without analgesic.  (II) Moderate pain reduction 
denoted 50% improvement and was considered 
Partial Pain Response (PPR). These patients had 
moderate pain and could sleep with simple 
analgesics. (III) No reduction of pain at all, or 
reduction of pain from very severe to severe, 
indicated 25% improvement and was considered No 
Pain Response (NPR). These patients had severe and 
intractable pain, and could not sleep even with strong 
analgesics.  
 
Exclusion criteria 
Patients who had received any systemic antiviral 
treatment within the four weeks preceding screening; 
subjects who were allergic to acyclovir or under 
treatment with drugs interacting with acyclovir; 
patients with liver or renal diseases; and patients with 
conditions that could interfere with gastrointestinal 
absorption of acyclovir were excluded from study. 
 
Treatment regimens 
All patients took acyclovir, 800 mg five times a 
day, for the first four days of the first week, followed 
by three treatment-free days. In the cases evidence of 
pain reduction but not CPR, a second course of 
treatment with the same dosage was offered. The 
patients were followed for three months without 
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medication. All patients were strictly advised not to 
use any topical or systemic drugs.  
 
Clinical response evaluation 
All patients were evaluated by a clinician as well 
as the patient’s self-assessment at each visit, in the 
form of a structured questionnaire in which patients 
were asked to score each variable as worse, no 
change, or improved after the therapy, as compared 
to the time before treatment was started. All patients 
were followed up to evaluate the efficacy of therapy 
at one, two, four, and twelve weeks after treatment. 
Tolerability to treatment was also assessed by using a 
three-point scale as follows: very good (no signs and 
symptoms); moderate (transient side-effects); and 
poor (adverse events which resulted in 
discontinuation of therapy). 
 
Statistical analysis 
Statistical analysis of the results was performed 
with the SPSS (Ver15for Windows) with the two-
tailed t-test, and Chi-Square test. In this analysis a p 
value of < 0.05 was considered significant. 
 
Results 
A total of 152 patients participated in the study, 
76 of whom were included in Group 1 (patients with 
a rash with a duration of less than 72 hours) and 76 of 
whom were included in Group 2 (patients with a rash 
with a duration of  more than 72 hours). 
 
Figure 1. The distribution of age at onset of herpes zoster 
 
 
 
 
 
Demographic characteristics 
Of the 152 participants, the youngest was 50 
years old and the oldest one was 85; the mean age 
was 62.2 (SD ± 9.3) (Figure 1). There were no 
significant differences between Group 1 and Group 2 
regarding age, gender, and clinical presentation. 
 
Dermatomes differences 
The thoracic area was the most common location 
of the herpes zoster lesions (n = 50; 32.9%), followed 
by the lumbosacral (n = 44; 28.9%), cervical (n = 33; 
21.7%), and trigeminal (n = 25, 16.4%) areas (Figure 
2). There were no significant differences in mean 
scores of dermatomes involvement among the 
patients (p = 0.348). 
 
Figure 2. Dermatomal distribution of herpes zoster lesions 
 
 
 
Duration of lesions healing 
Skin lesions rapidly healed and complete re-
epithelialization occurred in 7 to 10 days in Group 1 
and 12 to 25 days in Group 2. 
 
Acute zoster-associated pain 
The mean verbal rating scale scores were 3.77 ± 
0.6 versus 3.67 ± 0.44 (p = 0.73) in Group 1 and 
Group2, respectively.  Reduction in initial pain 
intensity (PPR) at Day 7 was obtained in 129 patients 
including 65patients (85.5%) in Group 1 and 64 
patients (84.2%) in Group 2. No significant 
difference between the two groups was evident (p = 
.821). On Day 7, almost 14.5% of Group 1 patients 
reported interference with sleep, as compared to 
15.8% of Group 2 patients (NPR).  
A further reduction in initial pain intensity (PPR) 
at Day 14 was obtained in 134 patients, 68 (89.5%) 
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of whom were from Group1 and 66 (86.8%) of whom 
were from Group 2. On Day 14, almost 13.2% of the 
patients in Group 2 had pain as compared with 10.6% 
of those in Group 1(NPR). No significant difference 
between the two groups was evident (p = .616). 
By the fourth week, 134 patients (88.2%) had 
absent or mild pain (CPR); 68 of these patients 
(89.5%) were from Group1 and 66 (86.8%) were 
from Group 2. On Day 28, almost 13.2% of the 
patients in Group 2 had pain as compared to 10.6% of 
the patients in Group 1. Again, no significant 
difference between the two groups was evident (p = 
.616). 
By the fourth week, the failure rate of our study 
(i.e., the patients who developed PHN), was 18 
patients (11.8%) (Figure 3). Among these 18 patients, 
nine had lumbosacral lesions, six had thoracic 
lesions, and three had trigeminal lesions. The 
incidence of PHN in male was higher than in female 
subjects, with 14 affected men (77.7%) compared to 
four affected women (22.3%).  
 
Figure 3. Percentage of patients who developed P.H.N by 
week 4. 
 
 
 
By the 12th week of patient follow-up, just six 
patients had PHN. At the end of study period, 146 
patients (96%) graded their pain as mild to no 
discomfort (CPR), and just six patients (4%) still had 
severe intractable pain (NPR). 
The results of VRS in Groups 1 and2 at the 
beginning of the study and after the first, second, 
fourth, and 16th weeks after treatment are shown in 
Table 1.  
The mean VRS score was not different between 
the two groups (3.77 ± 0.6 versus 3.67 ± 0. 0.44; p = 
0.73 in Groups 1 and 2 respectively) after four weeks. 
The mean VRS score changed significantly in both 
groups over the duration of the study (p = 0.001), but 
there was no difference between two groups (0.88 ± 
0.66 for Group 1 versus 0.94 ± 0.72 for Group 2; p = 
0.66). Furthermore, after three months, there was no 
difference between the treatment results in the two 
groups (0.51 ± 0.13 versus .0.54 ± 0.19; p = 0.77 for 
Group 1 and Group 2 respectively). 
 
Sessions of treatment 
In the first session of treatment, 118 patients 
(91.5%) achieved PPR. Following the treatment, 16 
patients (6.96%) achieved a further PPR in two 
different sessions. There was a significant difference 
in patient response to treatment in the two sessions of 
treatment in comparison to the first session (p =.003) 
(Figure 4). 
 
Figure 4. Percentage of complete pain response in first 
and second treatment sessions. 
 
 
 
Tolerance 
The overall treatment was well tolerated in most 
patients. None of the patients stopped treatment 
because of adverse effects of acyclovir. Tolerability 
of acyclovir was considered “very good” in 142 cases 
(93%), and “moderate” in 10 cases (7%). Six patients 
suffered from nausea and vomiting, five patients had 
fatigue, three patients developed skin rashes, and 
reversible BUN increase was detected in three 
patients. 
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Table 1. The patients’ post-herpetic pain results after first, second, fourth and twelfth week and one year after therapy 
 
 Group 1 (n = 76) Group 2 (n = 76)   p Value 
Mean VRS at beginning of study 3.77 ± 0.6 3.67 ± 0.44 (p = 0.73) NS 
Mean VRS after first week 2.19 ± 1.21 2.23 ± 1.19 (p = 0.76) NS 
PPR(%) after first week 65 (85.5%) 64 (84.2%) (p = 0.821) NS 
Mean VRS second week 2.10 ±1.11 2.12 ± 1.07 (p = 0.88) NS 
PPR (%) second week 68 (89.5%) 66 (86.6%) (p = 0.61) NS 
Mean VRS first month 0.88 ± 0.66 0.94 ± 0.72 (p = 0.66) NS 
CPR after first month  68 (89.5%) 66 (86.6%) (p = 0.61) NS 
Mean VRS third month 0.51 ± 0.13 0.54 ± 0.19 (p = 0.77) NS 
CPR after third month 74 (97.3%) 72 (94.7%) (p = 0.73)  NS 
Mean VRS twelfth month 0.32 ± 0.12 0.39 ± 0.14 (p = 0.88) NS 
CPR after twelfth month 75 (98.6%) 74 (97.3%) (p = 0.89)  NS 
 
VRS: Verbal Rating Scale (0-4) 
CPR: Complete Pain Response 
PPR: Partial Pain Response 
NS: Not statistically significant (p > 0.05) 
 
Discussion 
Herpes zoster is painful by itself and is 
sometimes followed by neuralgia. Post-herpetic 
neuralgia, defined as debilitating pain, persists 
beyond four weeks of rash onset. The risk of 
developing post-herpetic neuralgia rises with age, 
which influences both duration and severity of the 
neuralgia [15]. It may affect up to one half of patients 
over 50, and is very common after trigeminal nerve 
zoster [2].  
In some studies, the best predictor of persistent 
pain after herpes zoster was the presence of severe 
prodromal pain or severe pain at presentation and old 
age [16-20]. Female gender and cranial or sacral 
locations were additional risk factors for persistent 
pain in one of these studies [20]. 
Oral acyclovir (800 mg, administered orally five 
times a day for seven to ten days) has been shown to 
accelerate the rate of coetaneous healing of herpes 
zoster lesions and reduce the severity of acute pain 
[6,10-12,21-23]. In a reanalysis of the largest US 
placebo-controlled trial, the median duration of 
zoster-associated pain in acyclovir recipients was 20 
days, compared to 62 days for placebo recipients 
[24]. Early clinical trials have suggested that 
acyclovir has no benefit in reducing the duration of 
PHN [6,21,25] but more recent information supports 
the contrary. A meta-analysis of five clinical trials 
suggests that beginning oral administration of 
acyclovir within 72 hours of rash onset may reduce 
the incidence of residual pain within six months by 
46% in immunocompetent adults [26]. However, no 
study has indicated that antiviral therapy is not 
beneficial if it is started after 72 hours of rash onset. 
Wood et al. compared acyclovir administration for 
seven days to acyclovir administration for 21days, 
with and without prednisolone consumption, in the 
treatment of acute herpes zoster [27]. They found that 
treatment with acyclovir for 21 days, compared to 
seven days or the addition of prednisolone, did not 
reduce the frequency, duration or severity of PHN 
[27]. The findings of the present study add to this 
information that administration of acyclovir after the 
third day of the appearance of herpetic rash is just as 
effective in the treatment of post-herpetic neuralgia 
compared to early treatment (before 72 hours) with 
this agent.  
In our study, a significant improvement in pain 
intensity was evident by the seventh day of treatment 
in the majority of patients. Within two weeks of 
therapy, an excellent PPR was observed in 68 
patients of Group 1 (89.5%) and 66 patients of Group 
2 (86.8%). 
We showed that short-course oral acyclovir (800 
mg five times a day for four days), even if started 
within the first 21 days of zoster rash, was capable of 
shortening the healing  time and alleviating the 
severity acute zoster  pain as well as preventing PHN. 
Acyclovir proved to be successful within the first two 
weeks of treatment, providing remarkable 
improvement in acute zoster pain. All sites 
(trigeminal, cervical, thoracic, lumbosacral) showed 
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an equal response. In the present study similar daily 
doses (800 mg five times a day) administered for a 
short period of time (just for 4 days), cured 146 cases 
(96%) of acute herpes zoster pain (CPR). An early 
clinical response to acyclovir was observed in most 
patients of this study, even in those who received the 
drug after 72 hours of rash. We did not observe a 
significant difference in therapeutic responses with 
respect to rash duration. Seventy-six of the 152 
patients had suffered from the disease for a relatively 
short period of time (three days or less). The 
remaining76 cases had suffered from the disease for a 
longer period (4-21 days). Our study proved the 
efficacy of therapy which starts even after 72 hours 
of herpes zoster infection. Hence we think that the 
presence and activity of varicella-zoster virus beyond 
72 hours has a possible role in the persistence of 
acute herpes zoster pain and PHN. 
Another potential advantage of our therapy was the 
efficacy of short-course (four days) therapy in 
decreasing acute herpes zoster pain and preventing 
PHN. 
Based on these results, we propose that short-
course oral acyclovir (a four-day treatment) can be 
offered as an alternative to the 7-to 10-day therapy, 
particularly in an outpatient setting. To the best of 
our knowledge, no other study has compared the 
efficacy of acyclovir before and after the first 72 
hours of herpes zoster onset. 
Complete pain response was achieved after a 
mean of four weeks in both groups. Two sessions of 
treatments with acyclovir could not yield better 
results than a single treatment session. Our results 
also showed significantly lower rates of PHN 
compared with those reported in previously published 
data. Only six subjects in our study experienced PHN 
by the end of three months.  Pain intensity reduction 
on Day 7 versus Days 14 and 28 was significantly 
higher. The reason for this observation is unclear, but 
we think that the activity and living mass of the virus 
is one of the important causes of pain in HZ patients 
and more reduction in the mass of the living virus on 
the seventh day could be responsible for the higher 
pain reduction rating. While optimal therapy for 
herpes zoster is desired, safety aspects must be taken 
into account, and shorter courses of acyclovir therapy 
appear to result in fewer adverse effects than longer 
courses. 
 
Limitations  
This investigation has some limitations. First, due 
to the time-based evaluation of response to treatment, 
a double-blinded study was not possible. 
Additionally, the limited population under 
examination undermines a definitive conclusion that 
short-course acyclovir in all patients and in all 
populations can be safe and effective. Further 
proliferated studies with a larger number of patients 
are needed before the conclusion that this therapeutic 
method is completely effective in all HZ patients can 
be reached. 
 
Conclusion 
The results of this study show that short-course 
oral acyclovir (800 mg five times a day for four days) 
is capable of shortening the healing time and ending 
acute zoster pain, as well as preventing the 
occurrence of PHN, even if started within the first 21 
days of onset of zoster rash. These findings will be 
useful for physicians using this treatment protocol in 
treating HZ patients older than 50 years for 
prevention and treatment of PHN. 
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